Predictable Roles of Peripheral IgM Memory B Cells for the Responses to Anti-PD-1 Monotherapy Against Advanced Non-Small Cell Lung Cancer

Liliang Xia1,2†, Limin Guo3†, Jin Kang4†, Yi Yang1, Yaxian Yao1, Weimin Xia2, Ruiming Sun2, Shun Zhang2, Wenfeng Li4, Yuer Gao4, Hongyan Chen3, Ziming Li1, Jinji Yang4*, Shun Lu1* and Ying Wang2*

1 Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China, 2 Department of Immunology and Microbiology, Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, China, 3 Department of Genetic Engineering, School of Life Sciences and Institute of Biomedical Sciences, Fudan University, Shanghai, China, 4 Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, School of Medicine, Guangzhou, China

Tumor-infiltrating B cells and tertiary lymphoid structures have been identified to predict the responses to immune checkpoint inhibitors (ICIs) in cancer immunotherapy. Considering the feasibility of sample collection, whether peripheral B cell signatures are associated with the responses to ICI therapy remains unclear. Herein, we have defined peripheral B cell signatures in advanced non-small cell lung cancer (NSCLC) patients receiving anti-PD-1 monotherapy and investigated their associations with clinical efficacy. It was found that the percentages of B cells before the treatment (baseline) were significantly higher (P = 0.004) in responder (R, n = 17) than those in non-responder (NonR, n = 33) NSCLC patients in a discovery cohort. Moreover, the percentages of baseline IgM+ memory B cells were higher (P < 0.001) in R group than those in NonR group, and associated with a longer progression free survival (PFS) (P = 0.003). By logistic regression analysis peripheral baseline IgM+ memory B cells were identified as an independent prognostic factor (P = 0.002) for the prediction of the responses to anti-PD-1 monotherapy with the AUC value of 0.791, which was further validated in another anti-PD-1 monotherapy cohort (P = 0.011, n = 70) whereas no significance was observed in patients receiving anti-PD-L1 monotherapy (P = 0.135, n = 30). Therefore, our data suggest the roles of peripheral IgM+ memory B cells in predicting the responses to anti-PD-1 treatment in Chinese advanced NSCLC patients.

Keywords: immune checkpoint inhibitors, PD-1, peripheral IgM+ memory B cells, response prediction, advanced NSCLC
INTRODUCTION

Immune checkpoint inhibitors (ICIs) targeting programmed cell death1 (PD1) and its ligand (PD-L1) have greatly improved therapeutic outcomes in multiple carcinomas including advanced non-small cell lung cancer (NSCLC). However, the limited benefit population of ICI monotherapy makes it necessary to screen predictive biomarkers for stratifying the patients. Currently, PD-L1 expression on tumor cells has been used in clinic as an indicative biomarker (1). In addition, a high tumor mutation burden (2, 3), intratumor immunological signatures (4, 5), as well as increased diversity of gut microbiota (6, 7) are also reported to be associated with better responses to ICI treatment. Nevertheless, due to the difficulties in the collection of tumor biopsies from cancer patients and insufficient biomarkers to identify benefit patients, it is still necessary to investigate novel indicators associated with the responses to ICI treatment.

Peripheral blood is the most widely used specimen in clinical diagnosis. ICI treatment is demonstrated to affect the peripheral immune profiles. For instance, PD-1 blockade induces Ki67 expression in a subset of peripheral PD-1⁺CD8⁺ T cells and the expansion of neoantigen-specific T cell clones after anti-PD-1 treatment, which suggests the restoration of systematic anti-tumor immunity of CD8⁺ T cells after receiving ICI immunotherapy (8, 9). Therefore, several peripheral CD8⁺ T cell signatures have been reported to be associated with clinical outcomes of anti-PD-1/PD-L1 immunotherapy (8, 10). Our previous study also illustrated that high percentages of IFN-γ-producing naïve CD4⁺ T cells and PD-1⁺CD4⁺ memory T cells were associated with better response to anti-PD-1 treatment in NSCLC patients (11). Recently, B cells and tertiary lymphoid structures (TLSs) in the tumor microenvironment (TME) are identified to promote the responses to ICI treatment, illustrating the significance of B cells in anti-PD-1/PD-L1 immunotherapy (12–14). Whether systematic B cell signatures are associated with the responses to ICI therapy needs to be further explored.

In this study, peripheral B cell signatures from advanced NSCLC patients receiving anti-PD-1/PD-L1 monotherapy were systematically assessed by multiplex flow cytometry. Peripheral IgM⁺ memory B cells were identified to be associated with the responses to anti-PD-1 monotherapy in advanced NSCLC patients, providing the evidence on peripheral B cell signatures as a potential biomarker for stratifying the patients before the treatment.

METHODS

Patients

A total of 150 advanced NSCLC patients receiving ICI monotherapy were recruited in this study from Shanghai Chest Hospital affiliated to Shanghai Jiaotong University (n = 115) and Guangdong Provincial People’s Hospital (n = 35) from September 2017 to October 2020. Among them, 50 patients receiving nivolumab monotherapy after the failure of one to two prior systemic chemotherapies in Shanghai Chest Hospital were designated as a discovery cohort (cohort 1, Table 1). The advanced NSCLC patients received 240 mg nivolumab every two weeks. The responses to nivolumab treatment were evaluated every 8 weeks according to the

TABLE 1 | Clinical manifestations of advanced NSCLC patients receiving ICI treatments.

| Characteristics | Cohort 1 anti-PD-1 monotherapy (n = 50) | Cohort 2 anti-PD-1 monotherapy (n = 70) | Cohort 3 anti-PD-L1 monotherapy (n = 30) |
|-----------------|----------------------------------------|----------------------------------------|----------------------------------------|
| Age, year       | Median 61                               | Median 61                               | Median 62                               |
| Sex, n (%)      | Male 41 (82.0)                           | Male 57 (81.4)                           | Male 26 (86.7)                           |
|                 | Female 9 (18.0)                          | Female 13 (18.8)                         | Female 4 (13.3)                          |
| History, n (%)  | Squamous 17 (34.0)                       | Squamous 23 (32.9)                       | Squamous 12 (40.0)                       |
|                 | Non-squamous 33 (66.0)                   | Non-squamous 47 (67.1)                   | Non-squamous 18 (60.0)                   |
| Smoking status, n (%) | Smoker 39 (78.0) | Smoker 44 (62.9) | Smoker 23 (76.7) |
|                 | Nonsmoker 11 (22.0)                      | Nonsmoker 20 (28.6)                      | Nonsmoker 7 (23.3)                       |
|                 | Unknown 0 (0.0)                          | Unknown 6 (8.5)                          | Unknown 0 (0.0)                          |
| Disease stage, n (%) | III 8 (16.0)    | III 12 (17.1)                            | III 1 (3.3)                             |
|                 | IV 42 (84.0)                             | IV 58 (82.9)                             | IV 29 (96.7)                            |
| EGFR mutation, n (%) | Yes 6 (12.0)   | Yes 7 (10.0)                             | Yes 2 (6.7)                             |
|                 | No 37 (74.0)                             | No 44 (62.9)                             | No 28 (93.3)                            |
|                 | Unknown 7 (14.0)                         | Unknown 19 (27.1)                        | Unknown 0 (0.0)                          |
| Treatment, n (%) | First-line 0 (0.0)                       | First-line 19 (27.1)                     | First-line 15 (50.0)                     |
|                 | Second-line 45 (90.0)                    | Second-line 33 (47.1)                    | Second-line 10 (33.3)                    |
|                 | More than second 5 (10.0)                | More than second 18 (25.8)               | More than second 5 (16.7)               |
| Response        | R 17 (34.0)                              | R 24 (34.3)                              | R 15 (50.0)                             |
|                 | NonR 33 (66.0)                           | NonR 46 (65.7)                           | NonR 15 (50.0)                          |
| Median PFS (95% CI, days) | 70 (21-119)    | 80 (44-122)                              | 170 (60-280)                            |
RECIST 1.1 criteria. Accordingly, those whose tumor growth increased at least 20% were defined as progression diseases (PD), whereas decreased up to 30% were defined as partial response (PR) or stable disease (SD). Patients with PD within 180 days were annotated as non-responders (NonR) and those with SD + PR within 180 days were as responders (R). In addition, 70 advanced NSCLC patients receiving anti-PD-1 monotherapy (cohort 2, Table 1) and 30 advanced NSCLC patients receiving anti-PD-L1 monotherapy (cohort 3, Table 1) were recruited as independent validation cohorts, respectively. This study was approved by the Ethics Committee of Shanghai Chest Hospital (Number KS1732). All patients were informed of the study and consented to the enrollment. All the procedures were conducted in accordance with the Declaration of Helsinki.

Multi-Color Flow Cytometry
Whole blood was collected with anticoagulation and peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation using Lymphoprep™ reagent (Axis-shield, Oslo, Norway) according to the manufacturer’s instructions. Cells were stained with fluorochrome-conjugated monoclonal antibodies (mAbs) for multiplex flow cytometry analysis. Briefly, 1×10^6 PBMCs were resuspended in 100 μL FACS buffer (phosphate buffered saline supplemented with 2% fetal bovine serum) (Millipore, Bedford, MA, USA) and incubated with the mixtures of fluorochrome-conjugated mAbs targeting multiple cell surface markers including human CD3, CD8, CD19, CD16, CD27, CD38, CD24, PD-1, PD-L1, IgG and IgM (listed in Table S1). After incubation for 40 min at 4°C, cells were washed twice with 1 mL FACS buffer and resuspended in 200 μL FACS buffer. Cells were immediately acquired on LSR Fortessa (BD Pharmingen, San Diego, CA) and data analysis was performed with FlowJo software version 10 (Tree Star Inc., Ashland, Oregon).

Statistical Analyses
All the data were represented by mean ± standard error of mean (S.E.M). Statistical analyses were conducted by using SPSS 19.0 software (IBM SPSS Software, Armonk, NY, USA) or GraphPad Prism 6.0 (GraphPad Software Inc., San Diego, CA, USA). Tests for the differences between two groups were performed using a Wilcoxon test. Survival curves were performed by using the Kaplan-Meier method. The median frequencies were chosen as the cutoff to define the high and low group. P-values were calculated by the log-rank statistics in the Kaplan-Meier analyses. Multivariate analyses of the signatures associated with the responses to anti-PD-1 therapy were performed by using the logistic regression. The receiver operating characteristic (ROC) curves were constructed by plotting the true positive rate (sensitivity) against the false positive rate (1-specificity). P values were two-sided and P < 0.05 was considered statistically significant.

RESULTS
Patient Characteristics
A total of 120 advanced NSCLC patients receiving anti-PD-1 monotherapy and 30 patients receiving anti-PD-L1 monotherapy were recruited in this study (Table 1). Among those receiving anti-PD-1 monotherapy, 50 patients with nivolumab monotherapy were designated as a discovery cohort (cohort 1, Table 1) and another 70 patients were as a validation cohort (cohort 2, Table 1). Median days of the progression free survival (PFS) in cohort 1 and cohort 2 were 70 days (95% CI: 21-119 days) and 83 days (95% CI: 44-122 days), respectively according to the RECIST 1.1 criteria with no significant difference. In cohort 1, 17 patients (34.0%) with no disease progression in more than 180 days after nivolumab monotherapy were classified as R group, whereas 33 patients (66.0%) who had disease progression within 180 days were defined as NonR group. There were no significant differences in age, gender, smoking status and tumor stages etc. among R and NonR patients in cohort 1 (Table S2). Additionally, thirty patients receiving anti-PD-L1 monotherapy (cohort 3, Table 1) were included as another validation cohort.

High Percentages of Peripheral CD19+ B Cells at the Baseline in NSCLC Patients Are Associated With Good Responses to Anti-PD-1 Monotherapy
Previous investigates have addressed B cells and TLSs in the TME to promote the response to ICI immunotherapy (12–14). Considering the feasibility of peripheral blood in sample collection, we therefore investigated B cell signatures in advanced NSCLC patients and their associations with the responses to nivolumab monotherapy. Firstly, the expression profiles of PD-1 positive lymphocytes in the periphery of 50 advanced NSCLC patients were measured by multiplex flow cytometry. It was showed that among PD-1⁺ lymphocytes the percentages of B cells (31.90% ± 2.69%) were comparable with those of CD8⁺ T cells (29.35% ± 2.15%, P = 0.596), but significantly higher than those of CD8⁺ T cells (23.73% ± 2.61%, P = 0.011) and NK cells (13.35% ± 1.62%, P < 0.001) (Figure 1A). Peripheral B cells therefore accounted for a main proportion in PD-1 expressing lymphocytes. Subsequently, we compared the percentages of peripheral B cells at the baseline between R and NonR NSCLC patients in cohort 1. It was found that the percentages of CD19⁺ B cells in peripheral lymphocytes were higher in R (n = 17) than those in NonR patients (n = 33) (P = 0.004) (Figure 1B). More significantly, patients with high percentages of peripheral CD19⁺ B cells (median percentage as a cutoff value) showed a significantly longer PFS (median PFS: high vs. low = 188 vs. 55 days, P = 0.002) (Figure 1C). However, the percentages of PD-1 (Figure 1D) and PD-L1 expressing CD19⁺ B cells among periphery B cells (Figure 1E) were comparable between R and NonR patients, respectively. These results indicate that high percentages of peripheral CD19⁺ B cells are associated with better responses to nivolumab monotherapy in advanced NSCLC patients.

The Profiles of Peripheral IgM+ B Cell Subsets In Advanced NSCLC Patients Receiving Nivolumab Monotherapy
Peripheral B cells can be subgrouped into certain subsets with diverse functional implementations (15, 16). To further
investigate whether B cell subsets are associated with the responses to nivolumab monotherapy, we firstly compared the percentages of IgM+ and IgG+ B cells, two subsets with different functional definition (17), between R and NonR patients. Notably, the percentages of IgM+ B cells were higher in R patients than those in NonR patients (P < 0.001, Figure 2A). High percentages of IgM+ B cells were associated with a long PFS (median PFS: high vs. low = 206 vs. 55 days, P = 0.004) (Figure 2B). However, no significant differences in PD-1 and PD-L1 expressions on IgM+ B cells were observed between R and NonR patients either (Figures 2C, D). On the contrary, the percentages of IgG expressing B cells were lower in R patients (P = 0.032, Figure S1B) but with no associations to a better outcome (P = 0.312, Figure S1C).

B cells could be subgrouped into mature B cells (CD24+CD38-CD19+), memory B cells (CD27+CD19+), transitional regulatory B cells (CD24+CD38+CD19+) (tBreg) and plasmablasts (CD24-CD38+CD19+)(15, 16) (Figure S2). Differential expressions of IgM on B cell subsets were plotted in the t-distributed stochastic neighbor embedding (t-SNE) dimensionality reduction analysis in 13 advanced NSCLC patients of cohort 1 (Figures 3A, B). It was found that IgM expressions were high in mature B cells and tBreg cells, but low in memory B cells and plasmablasts (Figure 3C). It was notable that the percentages of IgM expressing mature B cells (Figure 3D), memory B cells (Figure 3E), tBreg cells (Figure 3F) and plasmablasts (Figure 3G) were higher in R patients than those in NonR patients, respectively. In line with the results from IgM+ B cells, high IgM expressions on B cell subsets were associated with a long PFS in the cohort 1 (Figures 3H–K). Collectively, our results further suggest that patients with more percentages of IgM expressing B cells as well as differentiation subsets at the baseline are inclined to respond better to nivolumab immunotherapy.

**Baseline IgM+ Memory B Cells Is Predictable for the Responses to Nivolumab Monotherapy**

Aforementioned results revealed that certain peripheral B cell signatures at the baseline were associated with good responses to nivolumab treatment in Chinese advanced NSCLC patients. We further used multivariate logistic regression to evaluate their predictive values. Among all the B cell signatures associated with longer PFS values (Table 2), the percentages of IgM+ memory B cells were the most significant in cohort 1 (P = 0.002) (Table 2). According to the ROC curve analysis, the Area Under Curve (AUC) values of IgM+ memory B cells reached 0.791 in cohort 1 (Figure 4A). What is more, the predictive significance of IgM+ memory B cells was validated in another cohort of advanced NSCLC patients receiving anti-PD-1 monotherapy (cohort 2 in Table 1, n = 70). In the validation cohort, higher percentages of baseline IgM+ memory B cells were detected in R group than those in NonR group (P = 0.011) (Figure 4B). The AUC value
reached 0.695 (Figure 4C). NSCLC patients with high percentages of IgM+ memory B cells displayed a longer PFS (median PFS: high vs. low = 121 vs. 47 days) ($P = 0.020$) (Figure 4D) as well. Significantly, a combination of baseline IgM+ memory B cell and CD4+ T memory cell percentages obtained from our previous study (11) (Table S3) achieved higher sensitivity for response prediction to anti-PD-1 treatment both in discovery cohort (AUC = 0.863) (Figure 4F) and validation cohort (AUC = 0.745) (Figure 4G) when compared to individual signature. However, the percentages of IgM+ memory B cells were comparable between R and NonR NSCLC patients receiving anti-PD-L1 monotherapy (cohort 3 in Table 1, n = 30) (Figure 4E), which suggests the distinct role of IgM+ memory B cells in predicting the efficacy of anti-PD-1 and anti-PD-L1 therapies. Our results thus indicate that the percentage of peripheral IgM+ memory B cells at the baseline is a novel indicator for predicting the responses to anti-PD-1 monotherapy in advanced NSCLC patients.

**Dynamics of PD-1 and PD-L1 Expressions on IgM+ Memory B Cells During Nivolumab Treatment**

Since baseline IgM+ memory B cells exhibited the potential in predicting anti-PD-1 treatment, we further investigated the expression profiles of PD-1 and PD-L1 on IgM+ memory B cells (Figure 5A). Our data showed that the percentages of PD-1 positive cells in IgM+ memory B cells were comparable to those in IgM+ memory B cells ($P = 0.803$), but significantly higher than those in IgM+ mature B cells ($P < 0.001$) (Figure 5B). In addition, the percentages of PD-L1 expressing cells on IgM+ memory B cells were significantly higher than those in IgM+ memory B cells ($P < 0.001$) and IgM+ mature B cells ($P < 0.001$) (Figure 5C), respectively.

We also analyzed the dynamics of IgM+ memory B cell percentages at the baseline and 8 weeks after anti-PD-1 treatment. There were no significant changes of IgM+ memory B cell percentages from the baseline to 8 weeks after the treatment in R and NonR patients (Figures S3G, H). However, the percentages of PD-1+IgM+ memory B cells were reduced in R patients ($P = 0.028$) at 8 weeks whereas no statistical change was observed in NonR patients ($P = 0.310$) (Figure 5D). On the contrary, the percentages of PD-L1+IgM+ memory B cells were increased in R patients ($P = 0.030$) at 8 weeks but stable in NonR patients ($P = 0.476$) (Figure 5E). Considering the high expression of PD-1 on IgM+ memory B cells, the reduction of PD-1+IgM+ memory B cells after 8 weeks in R patients might represent efficient interaction of nivolumab antibodies with unique B cell subset during the treatment.

**DISCUSSION**

T cells including CD8+ and CD4+ T cells play significant roles in mediating durable anti-tumor immunity (18–21), making them feasible in predicting the responses to ICI immunotherapy in clinic (8, 11, 22–24). Although B cells are mostly dedicated to humoral immunity against microbial infections, recent findings also illustrate response prediction significance of tumor-infiltrating B cells and TLSs in the patients with melanoma and sarcoma upon ICI treatment (12–14). In the present study, we have investigated the potential of peripheral B cells in predicting the responses to anti-PD-1/PD-L1 treatment in Chinese advanced NSCLC patients. In line with the findings in the TME, our results show that the percentage of CD19+ B cells at the baseline is higher in R than that in NonR group. What is more, the percentage of IgM+ memory B cells at the baseline is the most potential signature in predicting the responses to anti-PD-1 monotherapy.

B cells exert anti-tumor immunity mainly through antigen presentation and cytokine secretion for T cell activation (17, 25, 26). Although the exact mechanisms of B cells in facilitating the responses to ICI therapy need to be further investigated, it has been proposed that B cells as well as TLSs in tumor regions played critical roles in the activation of regional tumor-specific T
We also compared the infiltrating B cells in tumor biopsies between R (n = 3) and NonR (n = 12) patients before the treatment. No significant difference was observed between these two groups (Figure S4), which is similar to the results by Helmink BA et al. (13). Other studies also revealed the properties of infiltrating B cells associated with the responses to ICI treatment. For instance, clonal counts for both immunoglobulin heavy and light chains as well as BCR diversity were increased in the responders than those in the non-responders of melanoma patients upon neoadjuvant treatments

![Figure 3](image_url)
ICI therapy (13). Additionally, tumor associated B cells were found to sustain the inflammation in melanoma, which also facilitated the responses to ICI therapy (27). These results therefore provide the possible mechanism of infiltrating B cells on anti-tumor immunity in the TME.

In this study, we have demonstrated that high percentages of peripheral CD19+ B cells before the treatment were associated with a longer PFS in advanced NSCLC patients receiving nivolumab monotherapy. Compared to CD8+ T cells or NK cells, B cells account for a large proportion in PD-1 expressing lymphocytes (Figure 1A). PD-1 is previously reported to be engaged in regulating B cell-mediated humoral immunity (28, 29). We have also reported that blockade of PD-1 in mice augmented humoral immunity (28, 29). We have also reported that blockade of PD-1 in mice augmented humoral immunity (28, 29). We have also reported that blockade of PD-1 in mice augmented humoral immunity (28, 29). We have also reported that blockade of PD-1 in mice augmented humoral immunity (28, 29).

What is more, logistical regression analysis screened out IgM+ memory B cells as a novel indicator to predict the efficacy of anti-PD-1 monotherapy. Memory B cells are a B cell subset which is responsible for the maintenance of memory response upon microbial infection. Based on IgG and IgM expressions, they can be subdivided into long-lived IgM+ and class-switched IgG+ memory B cells. IgM+ memory B cells are demonstrated to play important roles in lasting long term immunity with less turnover (31). It has been reported that when encountering the same or similar antigens IgM+ memory B cells may reenter GCs to undergo further affinity maturation and isotype switch (32, 33). This subpopulation in the circulation has been associated with the outcome of the infections such as COVID-19 (34, 35). We have found that they expressed high level of PD-1 when compared to IgM+ mature B cells (Figure 5B). In addition, PD-L1 expression was much higher on IgM+ mature B cells than on both IgM- (mainly IgG+) memory B cells and IgM+ mature B cells (Figure 5C). More interestingly, upon anti-PD-1 treatment, there exhibited the decrease in peripheral PD-1+IgM+ memory B cells in R group than in NonR group whereas no similar trend

**FIGURE 4 | Significance of baseline IgM+ memory B cells in predicting the response to anti-PD-1 monotherapy.** (A) The Receiver Operating Characteristic (ROC) analyses of IgM+ memory B cell percentages in discovery cohort (cohort 1 in Table 1, n = 50). (B) Comparison of the percentages of IgM+ memory B cells between R(n = 24) and NonR (n = 46) advanced NSCLC patients with anti-PD-1 monotherapy in an independent validation cohort (cohort 2 in Table 1, n = 70). (C) The ROC analysis of IgM+ memory B cell percentages in validation cohort (cohort 2 in Table 1, n = 70). (D) The Kaplan-Meier analysis of the associations of the percentages of IgM+ memory B cells with the PFS in cohort 2. (E) Comparison of the percentages of IgM+ memory B cells between R (n = 15) and NonR (n = 15) advanced NSCLC patients with anti-PD-L1 monotherapy in an independent validation cohort (cohort 3 in Table 1, n = 30). (F, G) The ROC analyses of baseline CD19+ memory B combined with CD4+ memory T cell percentages in discovery cohort 1 (F) and validation cohort 2 (G). The Wilcoxon test was used to analyze the differences between two groups. Survival curves were plotted by using the Kaplan-Meier method using median as the cutoff to define the high and low group. P-values were calculated by the log-rank statistics in Kaplan-Meier analyses. **P < 0.01, ns, P > 0.05.
was observed in PD-1+IgM- memory B cells (data not shown). This might be explained that PD-1+IgM+ memory B cells might be one of the targets of anti-PD-1 antibody, which is similar to PD-1+CD8+ T cells reported previously (8, 10). Herein, we did not define how IgM+ memory B cells modulate anti-PD-1 regimen-mediated anti-tumor immunity in NSCLC patients. Given that IgM+ memory B cells are the main subpopulation in the secondary responses with high expressions of HLA-DR (Figure S6C), they might be engaged in promoting anti-tumor immunity through remodeling the capacity of antigen presentation upon nivolumab immunotherapy. In the future, whether IgM+ memory B cells migrate into the TME and how they interplay with T cells to enhance anti-tumor immunity merit further investigation. This might shed light on the mechanisms of B cells contributing to enhance ICI therapy.

In this study, since all the patients recruited have received at least one or two-rounds of chemotherapy before anti-PD-1 monotherapy, we also analyzed the effects of prior chemotherapy on peripheral B cells. It was showed that the prior chemotherapy has little effects on the proportions of peripheral CD19+ B cells at the beginning of anti-PD-1 monotherapy as well as the prognosis (Figure S7). Moreover, there was no significant difference in peripheral CD19+ B cell percentages between R and NonR patients at 2 and 8 weeks after the treatment (Figures S3A, C). No obvious changes were observed in the percentages of peripheral CD19+ B cells from the baseline to 8 weeks after immunotherapy either (Figures S3E, F). However, both peripheral CD19+ B cells and IgM+ memory B cell at the baseline were not associated with a longer OS (Figure S8). This might be due to the fact that B cell subsets are not the populations undergoing direct cytotoxicity against tumor cells. They are more likely to perform indirect function such as presenting tumor antigen for T cell activation, which might be more related to the PFS rather than OS.

Another interesting observation we got from this study is that the prediction roles of peripheral IgM+ memory B cells for anti-PD-1 monotherapy is not suitable for anti-PD-L1 monotherapy (Figure 4E). One of the reasons might be the sample size in anti-PD-L1 monotherapy cohort (n = 30). Another reason might be due to the different mechanisms of anti-PD-1 and anti-PD-L1 treatment against tumor. This is also demonstrated by our previous studies both in CD4+ T cell subsets (11) or metabolic biomarker signatures (36) for response prediction of ICI treatment in the same cohort. Our findings warrant further exploration in the prospective study with a larger advanced NSCLC population, as well as other types of tumors (37).

In summary, our study identified peripheral IgM+ memory B cells with high PD-1 and PD-L1 expressions as an alternative
potential indicator to predict the responses to anti-PD-1 monotherapy in Chinese advanced NSCLC. Since plenty of the signatures in the periphery have been identified independently including CD8+ T cells (8, 10), CD4+ T cells (24, 38), neutrophil-to-lymphocyte ratio (NLR) (39), monocytes (40), IL-8 (41, 42), LDH (43), as well as ctDNA (43, 44). How to integrate different signatures to establish multiparametric approaches to improve prediction efficacy will be significant in the future.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

All samples were collected in accordance with the Ethics Committee of Shanghai Chest Hospital-approved protocol (Number KS1732). All patients have provided written consent prior to blood collection.

AUTHOR CONTRIBUTIONS

YW, JY, and SL conceived and designed the study. LX, LG, WX, RS, and SZ performed the flow cytometric experiments. JK, YY, YY, WL, and YG were working on the clinical sample collection. LX, LG, JK, and YW performed data analysis. HC and ZL offered assistance and helpful discussions for data analysis. YW, SL, JY, and LX interpreted the results and drafted the manuscript. All authors contributed to the article and approved the submitted version.

REFERENCES

1. Gandini S, Massi D, Mandala M. PD-L1 Expression in Cancer Patients Receiving Anti PD-1/PD-L1 Antibodies: A Systematic Review and Meta-Analysis. *Crit Rev Oncol Hematol* (2016) 100:88–98. doi: 10.1016/j.critrevonc.2016.02.001

2. Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, et al. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. *Mol Cancer Ther* (2017) 16(11):2598–608. doi: 10.1158/1535-7163.MCT-17-0386

3. Hellmann MD, Cuieanu LE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valea C, et al. Nivolumab Plus Ipilimumab in Lung Cancer With a High Tumor Mutational Burden. *N Engl J Med* (2018) 378(22):2093–104. doi: 10.1056/NEJMoai1801946

4. Ayers M, Luceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, et al. IFN-Gamma-Related mRNA Profile Predicts Clinical Response to PD-1 Blockade. *J Clin Invest* (2017) 127(8):2930–40. doi: 10.1172/JCI91990

5. Thrommen DS, Koehler VH, Herzig P, Roller A, Trefny M, Dimeloe S, et al. A Transcriptionally and Functionally Distinct PD-1(+) CD8(+) T Cell Pool With Predictive Potential in Non-Small Cell Lung Cancer Treated With PD-1 Blockade. *Nat Med* (2018) 24(7):994–1004. doi: 10.1038/s41591-018-0057-z

6. Jin Y, Dong H, Xia L, Yang Y, Zhu Y, Shen Y, et al. The Diversity of Gut Microbiome Is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC. *J Thorac Oncol* (2019) 14(8):1378–89. doi: 10.1016/j.jtho.2019.04.007

7. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, et al. Gut Microbiome Modulates Response to Anti-PD-1 Immunotherapy in Melanoma Patients. *Science* (2018) 359(6371):97–103. doi: 10.1126/science.aan4236

8. Huang AC, Postow MA, Orlowski RJ, Mick R, Bentsch B, Manne S, et al. T-Cell Involvement in Tumour Burden Ratio Associated With Anti-PD-1 Response. *Nature* (2017) 545(7620):65–6. doi: 10.1038/nature22079

9. Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, et al. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. *N Engl J Med* (2018) 378(21):1976–86. doi: 10.1056/NEJMoai1716078

10. Kamphorst AO, Pillai RN, Yang S, Nasti TH, Akondy RS, Wieland A, et al. Proliferation of PD-1+ CD8 T Cells in Peripheral Blood After PD-1-Targeted Therapy in Lung Cancer Patients. *Proc Natl Acad Sci USA* (2017) 114(19):4993–98. doi: 10.1073/pnas.1705327114

11. Xia L, Wang H, Sun M, Yang Y, Yao C, He S, et al. Peripheral CD4(+) T Cell Signatures in Predicting the Responses to Anti-PD-1/PD-L1 Monotherapy for Chinese Advanced Non-Small Cell Lung Cancer. *Sci China Life Sci* (2021) 64(10):1590–601. doi: 10.1007/s11427-020-1861-5

12. Cabrita R, Lauss M, Sanna A, Donia M, Skaarup Larsen M, Mitra S, et al. Tertiary Lymphoid Structures Improve Immunotherapy and Survival in Melanoma. *Nature* (2020) 577(7791):561–65. doi: 10.1038/s41586-019-1914-8

13. Helmink RA, Reddy SM, Gao J, Zhang S, Rasar R, Thakur R, et al. B Cells and Tertiary Lymphoid Structures Promote Immunotherapy Response. *Nature* (2020) 577(7791):549–55. doi: 10.1038/s41586-019-1922-8

14. Petitprez F, de Reynes A, Keung EZ, Chen TW, Sun CM, Calderaro J, et al. B Cells Are Associated With Survival and Immunotherapy Response in Sarcoma. *Nature* (2020) 577(7791):556–60. doi: 10.1038/s41586-019-1906-8

15. Thomas J, Kupper M, Batra R, Jargosch M, Atenhan A, Baghin V, et al. Is the Humoral Immunity Dispensable for the Pathogenesis of Psoriasis? *J Investig Dermatol* (2019) 139(3):115–22. doi: 10.1111/jid.15101

16. Rosser EC, Mauri C. Regulatory B Cells: Origin, Phenotype, and Function. *Immunity* (2015) 42(4):607–12. doi: 10.1016/j.immuni.2015.04.005

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2021.759217/full#supplementary-material
17. Sharonov GV, Serebrovskaya EO, Yuzhakova DV, Britanova OV, Chudakov DM. B Cells, Plasma Cells and Antibody Repertoires in the Tumour Microenvironment. *Nat Rev Immunol* (2020) 20(5):294–307. doi: 10.1038/s41577-019-0257-x

18. Miller BC, Sen DR, Al Abyo H, Bi R, Kvakd YV, LaFleur MW, et al. Subsets of Exhausted CD8(+) T Cells Differentially Mediate Tumor Control and Respond to Checkpoint Blockade. *Nat Immunol* (2019) 20(3):326–36. doi: 10.1038/s41590-019-0132-6

19. Siddiqui I, Schaeuble K, Chennupati V, Fuertes Marraco SA, Calderon-Copete P, Sais Ferreira D, et al. Intratumoral Tc1(+)PD-1(+)CD8(+) T Cells With Stem-Like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy. *Immunity* (2019) 50(1):195–211.e10. doi: 10.1016/j.immuni.2018.12.021

20. Alspaeh EC, Lussier DM, Miceli AP, Khvatzov I, DuPage M, Luoma AM, et al. MHC-II Neoantigens Shape Tumour Immunity and Response to Immunotherapy. *Nature* (2019) 574(7780):696–701. doi: 10.1038/s41586-019-1671-8

21. Oh DY, Kwak SS, Raji SS, Li T, McCarthy E, Chow E, et al. Intratumoral CD4(+) T Cells Mediate Anti-Tumor Cytotoxicity in Human Bladder Cancer. *Cell* (2020) 181(7):1612–23 e13. doi: 10.1016/j.cell.2020.05.017

22. Sade-Feldman M, Yizhak K, Bjorgard SL, Ray JP, de Boer CG, Jenkins RW, et al. Defining T Cell States Associated With Response to Checkpoint Immunotherapy in Melanoma. *Cell* (2018) 175(4):998–1013.e20. doi: 10.1016/j.cell.2018.10.038

23. Zappasodi R, Budhu S, Hellmann MD, Postow MA, Senbabaoglu Y, Manne S, et al. Non-Conventional Inhibitory CD4(+)Foxp3(+)PD-1(+) T Cells as a Biomarker of Immune Checkpoint Blockade Activity. *Cancer Cell* (2018) 33(6):1017–32.e7. doi: 10.1016/j.ccell.2018.05.009

24. Zuoao M, Arasanz H, Fernandez-Hinojal G, Garcia-Granda MJ, Gato M, Bocanegra A, et al. Functional Systemic CD4 Immunity Is Required for Clinical Responses to PD-L1/PD-1 Blockade Therapy. *EMBO Mol Med* (2019) 11(7):e10293. doi: 10.15252/emmm.201910293

25. Michaud D, Steward CR, Mirilek B, Pylaeva-Gupta Y. Regulatory B Cells in Cancer. *Immunol Rev* (2021) 299(1):74–92. doi: 10.1111/imr.12939

26. Wang SS, Liu W, Ly D, Xu H, Qu L, Zhang L. Tumor-Infiltrating B Cells; Their Role and Application in Anti-Tumor Immunity in Lung Cancer. *Cell Mol Immunol* (2019) 16(1):16–18. doi: 10.1038/s41423-018-0027-x

27. Griss J, Bauer W, Wagner C, Simon M, Chen M, Grabmeier-Pfisterhansler K, et al. B Cells Sustain Inflammation and Predict Response to Immune Checkpoint Blockade in Human Melanoma. *Nat Commun* (2019) 10(1):4186. doi: 10.1038/s41467-019-12160-2

28. Khan AR, Hams E, Foudas A, Sparwasser T, Weaver CT, Fallon PG. PD-L1hi B Cells Are Critical Regulators of Humoral Immunity. *Nat Commun* (2015) 6:5997. doi: 10.1038/ncomms6997

29. Good-Jacobson KL, Szumilas CG, Chen L, Sharpe AH, Tomayko MM, et al. Expansion of Plasmablasts and Loss of Memory B Cells in Early Inflammatory Responses and Secondary Germinal Center Reactions. *Proc Natl Acad Sci USA* (2015) 112(6):E546–55. doi: 10.1073/pnas.1416276112

30. Zhang M, Xia L, Gao F, Liu L, Yang Y, Chen Y, et al. Serum Metabolite Biomarkers Predictive of Response to PD-1 Blockade Therapy in Non-Small Cell Lung Cancer. *Front Mol Biosci* (2021) 8:678753. doi: 10.3389/fmbio.2021.678753

31. Yuan S, Liu Y, Till B, Song Y, Wang Z. Pretreatment Peripheral B Cells Are Associated With Tumor Response to Anti-PD-1-Based Immunotherapy. *Front Immunol* (2020) 11:563633. doi: 10.3389/fimmu.2020.563633

32. Kagami H, Kitano S, Yamaguchi O, Yoshimura K, Horimoto K, Kitazawa M, et al. CD4(+) T-Cell Immunity in the Peripheral Blood Correlates With Response to Anti-PD-1 Therapy. *Cancer Immunol Res* (2020) 8(3):334–44. doi: 10.1158/2326-6066.CIR-19-0574

33. Russo A, Russano M, Franchina T, Migliorino MR, Apriile G, Mansueto G, et al. Neutrophil-To-Lymphocyte Ratio (NLR), Platelet-To-Lymphocyte Ratio (PLR), and Outcomes With Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study. *Adv Ther* (2020) 37(3):1145–53. doi: 10.1007/s12323-020-01229-w

34. Krieg C, Nowicka M, Guglietta S, Schindler S, Hartmann FJ, Weber LM, et al. High-Dimensional Single-Cell Analysis Predicts Response to Anti-PD-1 Immunotherapy. *Nat Med* (2018) 24(2):144–53. doi: 10.1038/nm.4466

35. Schalper KA, Carleton M, Zhou M, Chen T, Feng Y, Huang SP, et al. Elevated Serum Interleukin-8 Is Associated With Enhanced Intratumor Neutrophils and Reduced Clinical Benefit of Immune-Checkpoint Inhibitors. *Nat Med* (2020) 26(5):688–92. doi: 10.1038/s41591-020-0858-x

36. Yuen KC, Liu LF, Gupta V, Madireddi S, Keerthivasan S, Li C, et al. High Systemic and Tumor-Associated IL-8 Correlates With Reduced Clinical Benefit of PD-L1 Blockade. *Nat Med* (2020) 26(5):693–98. doi: 10.1038/s41591-020-0860-1

37. Yuan S, Xia Y, Shen L, Ye L, Li L, Chen L, et al. Development of Nomograms to Predict Therapeutic Response and Prognosis of Non-Small Cell Lung Cancer Patients Treated With Anti-PD-1 Antibody. *Cancer Immunol Immunother* (2021) 70(2):533–46. doi: 10.1007/s00262-020-02710-9

38. Wang Z, Duan J, Wang G, Zhao J, Xu J, Han J, et al. Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors. *J Thorac Oncol* (2020) 15(4):556–67. doi: 10.1016/j.jtho.2019.12.001

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

**Copyright © 2021** Xia, Guo, Kang, Yang, Yao, Xia, Sun, Zhang, Li, Guo, Chen, Li, Yang, Lu and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.